Medical Director - Medicare Appeals
CVS HealthFull Time
Mid-level (3 to 4 years)
Candidates must possess an advanced scientific degree or equivalent (e.g., PharmD, PhD, MD) and at least 8 years of experience in the pharmaceutical industry, managed care, or HEOR roles. Experience as a payer-focused field medical liaison, in account management, formulary management, trade/rebate, Director of Pharmacy, academic detailing, or economic modeling/HEOR is required. Experience with neuromuscular disorders, rare diseases, specialty drugs, and accelerated approval drugs is highly desired, and prior launch experience is a plus. A strong understanding of the US payer system is essential.
The Director, Managed Markets Liaison will serve as a medical lead engaging with payers and healthcare decision-makers on scientific, health economic, and disease state exchanges. They will develop strategic customer account plans aligned with medical and access strategies, build relationships with key customers, and gather customer insights to inform company and access strategy. This role involves responding to medical information requests, serving as an internal subject matter expert, and providing training. Responsibilities also include supporting the development of payer-facing tools, building awareness within the payer community, supporting HEOR initiatives, and demonstrating thorough knowledge of the company's products and the payer landscape. The individual will attend key conferences, provide strategic leadership and mentorship within the team, and collaborate with internal departments to ensure a customer-centric and compliant approach. Efficient management of administrative tasks, including CRM updates and expense reporting, is also required.
Develops AI-optimized gene therapy vectors
Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.